Valuation: Syntara Limited

Market Cap 27.48M 18.55M 16.86M 15.57M 14.07M 26.55M 1.74B 187M 74.21M 935M 69.62M 68.15M 2.96B P/E 2027 *
-2.8x
P/E 2028 * -4.67x
Enterprise Value -5.32M -3.59M -3.26M -3.01M -2.72M -5.14M -337M -36.24M -14.36M -181M -13.47M -13.19M -573M EV / Sales 2027 *
-
EV / Sales 2028 * 0.43x
Free-Float
71.1%
Yield 2027 *
-
Yield 2028 * -
1 week-26.32%
Current month-24.32%
1 month-26.32%
3 months-46.15%
6 months-46.15%
Current year-60.00%
1 week 0.01
Extreme 0.01300000
0.02
1 month 0.01
Extreme 0.01300000
0.02
Current year 0.01
Extreme 0.01300000
0.04
1 year 0.01
Extreme 0.01300000
0.04
3 years 0.01
Extreme 0.01300000
0.1
5 years 0.01
Extreme 0.01300000
0.12
10 years 0.01
Extreme 0.01300000
0.37
Manager TitleAgeSince
Chief Executive Officer 64 2013-03-11
Chief Tech/Sci/R&D Officer - 2022-06-30
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Director/Board Member 64 2013-03-11
Chairman 68 2023-10-02
Director/Board Member - 2022-12-15
Date Insider Type Main position Quantity % Market Cap. Importance
3/13/25 Buy

Director

9,753,442 0.6008%
9/24/24 Buy

Director

53,571,429 4.1513%
8/12/21 Expiration

Chief Executive Officer

471,000 0.1040%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-26.32%-53.33%-54.84% 18.63M
-1.29%-3.91%+51.98%+69.06% 66.33B
-0.09%+2.79%+12.54%+95.02% 60.62B
+0.63%+1.64%+23.11%+89.70% 55.5B
-1.26%-1.45%+12.43%+117.42% 47.58B
-0.15%-5.06%+20.00%+29.27% 43.69B
-3.15%-16.63%+146.30%+685.27% 37.27B
+0.23%+2.14%+14.85%+46.22% 36.57B
+2.35%-3.61%+80.65%+60.70% 32.22B
+1.42%+5.84%-36.40%+402.78% 26.58B
Average -0.13%-2.09%+27.21%+154.06% 41B
Weighted average by Cap. -0.29%-1.12%+35.88%+152.75%

Financials

2027 *2028 *
Net sales - 5.5M 3.71M 3.37M 3.12M 2.82M 5.31M 349M 37.48M 14.85M 187M 13.93M 13.64M 593M
Net income -31.85M -21.5M -19.54M -18.05M -16.3M -30.77M -2.02B -217M -86M -1.08B -80.69M -78.98M -3.43B -31.5M -21.27M -19.32M -17.85M -16.12M -30.43M -2B -215M -85.06M -1.07B -79.8M -78.11M -3.39B
Net Debt -32.8M -22.14M -20.12M -18.59M -16.79M -31.69M -2.08B -224M -88.57M -1.12B -83.09M -81.34M -3.53B -25.1M -16.95M -15.4M -14.22M -12.85M -24.25M -1.59B -171M -67.78M -854M -63.59M -62.24M -2.7B
Projected Income Statement - Annual - Syntara Limited
Logo Syntara Limited
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing topical pan-LOX inhibitors in scar revision, keloid scarring and scar prevention post-surgery. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
Employees
-
Date Price Change Volume
26-11-16 A$0.0140 0.00% 1,562,461
26-11-13 A$0.0140 0.00% 1,656,222
26-11-12 A$0.0140 0.00% 2,353,641
26-11-11 A$0.0140 -12.50% 4,583,481
26-11-10 A$0.0160 -15.79% 14,284,984
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Syntara Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0140AUD
Average target price
0.1050AUD
Spread / Average Target
+650.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Syntara Limited